Navigation Links
Novel compounds show promise as safer, more potent insecticides

Research teams at Nihon Nohyaku Co., Ltd., Bayer CropScience and DuPont have developed two new classes of broad-spectrum insecticides that show promise as a safer and more effective way to fight pest insects that damage food crops. The insecticides, which represent the first synthetic compounds designed to activate a novel insecticide target called the ryanodine receptor, may also help tackle the growing problem of insecticide resistance, the researchers say. They described their studies today at the 230th national meeting of the American Chemical Society, the world’s largest scientific society.

Many of the most widely used insecticides today act on only a handful of exploited targets, including the organophosphates, which block acetylcholinesterase, an enzyme that helps control nerve activity. Some experts are concerned that these older, less-selective insecticides could pose heath risks and there’s a growing effort underway to find safer replacements.

Targeting the ryanodine receptor may offer a promising alternative, researchers say. Ryanodine, a natural alkaloid discovered years ago in a species of tropical plant, has been used to study muscle physiology in a wide variety of organisms, including insects and mammals. Ryanodine receptors regulate muscle and nerve activities by modifying levels of internal calcium in these cells. These receptors exist in both mammals and insects but have distinct differences. Researchers have known that ryanodine itself has insecticidal properties, but no synthetic molecules had previously been identified that potently and selectively target these receptors in insects, until now.

Nihon Nohyaku Co., Ltd., based in Japan, and Bayer CropScience AG in Germany have jointly developed Flubendiamide, the first example of the phthalic acid diamides, a novel class of insecticides that activate the ryanodine receptor. The insecticide is highly effective against many different species of caterpillars, says Masanori Tohni
'"/>

Source:American Chemical Society


Page: 1 2

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Novel technology detects human DNA mutations
3. Novel antiviral technology inhibits RSV infection in mice
4. Novel Enzyme Shows Potential As An Anti-HIV Target
5. Novel Therapy Tested in Mice Could Chase Away Cat Allergies
6. Discovery Could Lead To Novel Approaches In HIV Treatment
7. Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells
8. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
9. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
10. Novel live reporting system to track cells
11. Field of beams - Novel system uses polarized light pulses to reveal crop health
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Novel compounds show promise safer more potent insecticides

(Date:5/29/2015)... May 28, 2015 Research and Markets ... the "Facial Recognition Market by Solution, by ... Forecast to 2020" report to their offering. ... facial recognition technology become more efficient and cost ... traction and investment from the commercial sector. The ...
(Date:5/28/2015)... 28, 2015 Industry analyst firm n-tech ... report titled "Markets for Self-Healing Materials: 2015-2022." According to ... and vascular systems, biomaterials, relevant shape memory materials ... $2.7 billion by 2020. The report ... of smart materials. Other recent n-tech reports have included ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... contact the Communications and External Relations staff member identified at the ... research and development activities, please refer to one of our Media ... can send it to news@ornl.gov . ... recovering from injuries, the elderly and even athletes could one day ...
... CHAMPAIGN, lll. A protein that helps pack DNA into ... activity, scientists report. The researchers found that the protein, histone ... cellular workbenches on which all proteins are made. The ... Cell Biology . A human cell,s genetic material is ...
... occurrence of fishes in the ocean,s deepest reachesthe hadal zone, ... are more numerous at such depths than experts had thought. ... July/August issue of BioScience , observed 10 to 20 ... baited video lander in the Japan Trench. The observation period ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory July 2010 2Story tips from the Department of Energy's Oak Ridge National Laboratory July 2010 3Histone H1 regulates gene activity throughout the cell cycle 2Histone H1 regulates gene activity throughout the cell cycle 3Study suggests more fish than thought may thrive in the ocean's depths 2
(Date:5/30/2015)... May 30, 2015 The Cholangiocarcinoma ... research for bile duct cancer, announced today the ... Fellowship Program. , The Foundation has ... throughout the country to raise awareness about cholangiocarcinoma ... support research that opens new pathways for diagnosis ...
(Date:5/30/2015)... 2015 CTI BioPharma Corp. (CTI BioPharma) (NASDAQ ... BAX ) today announced data from PERSIST-1 – ... the treatment of myelofibrosis – in a late-breaking oral ... American Society of Clinical Oncology (ASCO), May 29-June 2, ... is an investigational oral multikinase inhibitor with specificity for ...
(Date:5/30/2015)... and RARITAN, N.J. , ... multi-center, open-label, two-part, single-arm Phase 2 MMY2002 (SIRIUS) ... investigational, human anti-CD38 monoclonal antibody – achieved an ... CI, 20.8-38.9), as assessed by an independent review ... The ORR was consistent among the pre-specified subgroups ...
(Date:5/30/2015)... May 30, 2015  Caris Life Sciences® today ... in which researchers identified biomarker changes, including key ... tumors, indicating changes in response to therapy as ... was a subset of a larger study analyzing ... the cancer. These data utilizing Caris Molecular Intelligence®, ...
Breaking Biology Technology:The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 2Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 3Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 4Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 5Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 6Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 7Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 8Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 9Phase 3 Pacritinib Study Shows Significant Clinically Meaningful Results In Patients With Myelofibrosis In Late-Breaking Session At ASCO 2015 10Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 2Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 3Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 4Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 5Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 6Data Show Daratumumab Achieved a Pronounced Overall Response Rate as a Single-Agent with Tolerable Safety Profile in Heavily Pre-Treated Multiple Myeloma Patients 7Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 2Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 3Caris Life Sciences Paired Tumor Data Identifies Key Driver Mutations and Confirms Tumor Heterogeneity in High-Grade Glioma Samples 4
... 2009 Waukesha Electric Systems, SuperPower, University of Houston, Oak ... in a $10.7 million smart grid demonstration project award ... on November 24. The funds will be used to ... the reliability of the nation,s power grid. , ...
... 22 /PRNewswire/ - Viron Therapeutics Inc., a biotechnology company ... that it has been granted U.S. patents related to ... These patents join a portfolio of more than 80 ... drug discovery platform identifies proteins expressed by non-human viruses ...
... , , , , SEATTLE, Dec. 22 ... announced today its support of the Pharmaceutical Research Manufacturers ... revised July 2008" (PhRMA Code). Adherence to the ... , "As CTI prepares for the potential launch ...
Cached Biology Technology:Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 2Waukesha Electric partners with SuperPower and UH to build fault current limiting superconducting transformer for Dept. of Energy 3Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates 2Viron granted U.S. Patents for Organ Transplant and Arthritis Drug Candidates 3Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals 2Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals 3Cell Therapeutics Commits to PhRMA's Code on Interactions With Healthcare Professionals 4
... Rotor for use in the ... and Centra-MP4/MP4R. Perfect for ... and other difficult to separate ... containment. Complete with rotor and ...
Buckets for 2 racks of 5 tubes, type Stago/Hitachi...
Buckets for tube holder inserts...
Rotor for four tube-loaded buckets; ma RCF 2550g; sold without buckets...
Biology Products: